ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Versatile Targeted Celastrol Nanoassemblies for Enhanced Immunomodulatory Effects Against MRSA Infection.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The escalating crisis of antimicrobial resistance, driven by pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), underscores the urgent demand for innovative therapeutic strategies that outperform conventional antibiotic regimens. In this study, we developed a versatile targeted celastrol nanoassembly (CDPG) that integrates site-specific antibacterial delivery with coordinated immunomodulation to effectively address MRSA infections and prevent their recurrence. The nanoassembly consists of a celastrol-dextran antibacterial core encapsulated by a polyethylene glycol (PEG) shell, which is linked via pH-sensitive boronate ester bonds and stabilized through the reconstitution of the β-glucan triple-helix structure. This design enables prolonged systemic circulation under physiological conditions. Upon reaching the acidic microenvironment of the bacterial infection site, the nanoassembly undergoes PEG layer dissociation, exposing dextran moieties that enhance pathogen targeting through lectin-mediated recognition, while simultaneously releasing β-glucan to activate both innate and adaptive immune responses. In murine models of MRSA infection, CDPG demonstrated precise accumulation at lesion sites, potent bactericidal efficacy, modulation of inflammatory responses, and induction of systemic immune activation upon rechallenge. This study presents a natural product-derived, rationally designed nanomedicine strategy that integrates stimulus-responsive structural transformation, pathogen-targeted drug delivery, and modulation of the host immune system, offering a hopeful therapeutic approach to combat multidrug-resistant bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.